Suscriptores   Asóciese  
Textos Completos Autorizados
NUEVOS MARCADORES MICROBIOLOGICOS DE LA HEPATITIS C

v-aproveche-su-tiempo-estudie-en-espanol.png
Expertos Invitados





NUEVOS MARCADORES MICROBIOLOGICOS DE LA HEPATITIS C

(especial para SIIC © Derechos reservados)
Revisión de las nuevas técnicas microbiológicas desarrolladas para mejorar el diagnóstico y el tratamiento de la hepatitis C.
rodriguezdiaz9.jpg Autor:
Juan Carlos Rodríguez Díaz
Columnista Experto de SIIC

Institución:
Sección de Microbiología, Hospital General Universitario de Elche

Artículos publicados por Juan Carlos Rodríguez Díaz
Coautores
Montserrat Ruiz García* Gloria Royo García** 
Dr. en Medicina, Esp. en Microbiología, Sección de Microbiología, Hospital General Universitario de Elche, Elche, España*
Dr. en Farmacia, esp. en Microbiología, Sección de Microbiología, Hospital General Universitario de Elche, Elche, España**
Recepción del artículo
17 de Marzo, 2006 		Aprobación
28 de Marzo, 2006
Primera edición
25 de Julio, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

NUEVOS MARCADORES MICROBIOLOGICOS DE LA HEPATITIS C

Resumen
La hepatitis C es un importante problema de salud pública, ya que afecta al 2% de la población mundial. Las nuevas técnicas microbiológicas basadas en la biología molecular proporcionan herramientas muy útiles para mejorar el diagnóstico, la prevención y el tratamiento de esta enfermedad. En esta revisión se exponen los últimos avances de estas técnicas, haciendo hincapié en la importancia de la genotipificación de las cuasiespecies virales y de la detección viral mediante la búsqueda del antígeno del core y del ARN viral, así como en la utilidad de la secuenciación en la detección de resistencia a fármacos y en el estudio de la epidemiología del virus.

Palabras clave
hepatitis C, diagnóstico, técnicas moleculares, secuenciación


Artículo completo
(castellano)
Extensión:  +/-5.19 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

NEW MICROBIOLOGICAL MARKERS OF HEPATITIS C

Abstract
Hepatitis C is a serious public health problem because it infects 2% of world population. The new microbiological tools based on molecular biology are very useful to diagnose, prevent and treat this disease. This review shows the progress in these technologies, focusing in the importance of genotypes and viral quasispecies, as well as in the importance of the study of Ag of core and RNA detection. It also deals with the utility of the secuenciation in drugs resistance detection and virus epidemiology.

Key words
hepatitis C, diagnosis, molecular tools, secuenciation

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Infectología
Relacionadas: Bioquímica, Diagnóstico por Laboratorio, Gastroenterología, Medicina Interna



Comprar este artículo
Extensión: 5.19 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Juan C. Rodríguez Díaz, Hospital General Universitario de Elche, 03203, Camí de l'Almàssera 11, Elche, España
Bibliografía del artículo
1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
2. Sánchez Quijano A, Abad MA, Torronteras R, y col. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997; 27:25-29.
3. Cha TA, Beall B, Irvine J, y col. At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci USA 1992; 89:7144-7148.
4. Silva GF, Nishimura NF, Coelho KI, Soares EC. Grading and staging chronic hepatitis C and its relation to genotypes and epidemiological factors in Brazilian blood donors. Braz J Infect Dis 2005; 9:142-149.
5. Focaccia R, Baraldo DC, Ferraz ML. Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. Braz J Infect Dis 2004; 8:348-355.
6. Amorim RM, Oliveira CP, Wyant PS, y col. Hepatitis C virus genotypes in blood donors from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 2004; 99:895-897.
7. Soza A, Arrese M, González R, y col. Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C. Ann Hepatol 2004; 3:146-151.
8. Cantaloube JF, Gallian P, Attoui H, Biagini P, De Micco P, De Lamballerie X. Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J Clin Microbiol 2005; 43:3624-3629.
9. Roque Afonso AM, Ducoulombier D, Di Liberto G, y col. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005; 79:6349-6357.
10. Blatt LM, Mutchnick MG, Tong MJ y col. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7:196-202.
11. Smith DB, Davidson F, Yap P, y col. International HCV Collaborative Study Group. Levels of hepatitis C virus in blood donors infected with different viral genotypes. J Infect Dis 1996; 173:727-730.
12. Lau JY, Davis GL, Prescott LE, y col. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996; 124:868-876.
13. Margraf RL, Erali M, Liew M, Wittwer CT. Genotyping hepatitis C virus by heteroduplex mobility analysis using temperature gradient capillary electrophoresis. J Clin Microbiol 2004; 42:4545-4551.
14. Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL et al. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6:203-8.
15. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. Hemophilia growth and development study. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191:4-10.
16. Van Asten L, Prins M. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS 2004; 18:2319-2324.
17. Hultgren C, Desombere I, Leroux-Roels G, y col. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004; 40:971-978.
18. Rolfe KJ, Alexander GJ, Wreghitt TG, Parmar S, Jalal H, Curran MD. A real-time Taqman method for hepatitis C virus genotyping. J Clin Virol 2005; 11.
19. Laperche S, Lunel F, Izopet J, y col. Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 2005; 43:733-739.
20. Zekri AR, El-Din HM, Bahnassy AA, y col. TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. J Med Virol 2005; 75:412-420.
21. Lagging LM, García CE, Westin J, y col. Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol 2002; 40:4224-4229.
22. Gaudy C, Thevenas C, Tichet J, Mariotte N, Goudeau A, Dubois F. Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup. J Clin Microbiol 2005; 43:1722-1726.
23. Gonzalez V, Padilla E, Diago M, y col. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2005; 12:481-487.
24. Enomoto M, Nishiguchi S, Tamori A, y col. Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. J Med Virol 2005; 77:77-82.
25. Massaguer A, Forns X, Costa J, y col. Performance of hepatitis C virus core antigen immunoassay in monitoring viral load after liver transplantation. Transplantation 2005; 79:1441-1444.
26. Herring BL, Tsui R, Peddada L, Busch M, Delwart EL. Wide range of quasispecies diversity during primary hepatitis C virus infection. J Virol 2005; 79:4340-4346.
27. Seme K, Poljak M, Babic DZ, Mocilnik T, Vince A. The role of core antigen detection in management of hepatitis C: a critical review. J Clin Virol 2005; 32:92-101.
28. Laperche S, Le Marrec N, Girault A, y col. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43:3877-3883.
29. Tang KH, Herrmann E, Cooksley H, y col. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005 Aug 31; [Epub ahead of print].
30. Carlsson T, Reichard O, Norkrans G, y col. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005; 12:473-480.
31. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005; 46:290-300.
32. Schroeter M, Zoellner B, Polywka S, Laufs R, Feucht HH. Prolonged time until seroconversion among hemodialysis patients: the need for HCV PCR. Intervirology 2005; 48:213-215.
33. Glynn SA, Wright DJ, Kleinman SH, y col. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45:994-1002.
34. Castillo I, Rodriguez-Inigo E, Bartolome J, y col. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005; 54:682-685.
35. Zhang W, Huang J, Zhou MF, y col. Protein chip for detection of different HCV antibodies: preparation, quality control, and clinical evaluation. Mol Diagn 2005; 9:81-87.
36. De Cock L, Hutse V, Vranckx R. Correlation between detection of antibodies against hepatitis C virus in oral fluid and hepatitis C virus RNA in serum. Eur J Clin Microbiol Infect Dis 2005 Aug 19; [Epub ahead of print].
37. Layden-Almer JE, Kuiken C, Ribeiro RM, y col. Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 2005; 192:1078-1087.
38. Soderholm J, Ahlen G, Kaul A, y col. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut. 2005 Aug 16; [Epub ahead of print].
39. Hamano K, Sakamoto N, Enomoto N, y col. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol 2005; 20:1401-1409.
40. Tanabe Y, Nagayama K, Enomoto N, y col. Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy. J Viral Hepat 2005; 12:251-261.
41. Yoshioka K, Ito H, Watanabe K, y col. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection. J Viral Hepat 2005; 12:139-145.
42. Watanabe K, Yoshioka K, Yano M, y col. Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A. J Med Virol 2005; 75:504-512. 43. Pascu M, Martus P, Hohne M, y col. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004; 53:1345-1351.
44. Schuttler CG, Thomas C, Discher T, Friese G, Lohmeyer J, Schuster R, Schaefer S, Gerlich WH. Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera. J Clin Microbiol 2004; 42(5):1977-81.
45. Marinosci F, Bergamini C, Fransvea E, y col. Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin. J Interferon Cytokine Res 2005; 25:453-458.
46. Krekulova L, Rehak V, Riley LW. Hepatitis C virus (HCV) 5'NC sequence variants and their association with hepatitis C risk groups. J Clin Virol 2005; 32:300-304.
47. Chambers TJ, Fan X, Droll DA, y col. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005; 79:3071-3083.
48. Bracho MA, Gosalbes MJ, Blasco D, Moya A, Gonzalez-Candelas F. Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit. J Clin Microbiol 2005; 43:2750-2755.
49. Othman SB, Trabelsi A, Monnet A, y col. Evaluation of a prototype HCV NS5b assay for typing strains of hepatitis C virus isolated from Tunisian haemodialysis patients. J Virol Methods 2004; 119:177-181.
50. Combet C, Penin F, Geourjon C, Deleage G. HCVDB: hepatitis C virus sequences database. Appl Bioinformatics 2004; 3:237-240.
51. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21:379-384.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517